Page last updated: 2024-10-23

buflomedil and Intermittent Claudication

buflomedil has been researched along with Intermittent Claudication in 38 studies

buflomedil: RN given refers to parent cpd; synonym LL 1656 refers to HCl; structure

Intermittent Claudication: A symptom complex characterized by pain and weakness in SKELETAL MUSCLE group associated with exercise, such as leg pain and weakness brought on by walking. Such muscle limpness disappears after a brief rest and is often relates to arterial STENOSIS; muscle ISCHEMIA; and accumulation of LACTATE.

Research Excerpts

ExcerptRelevanceReference
"A meta-analysis was performed on the results of clinical trials of buflomedil in intermittent claudication."10.17A meta-analysis of randomized, double-blind, placebo-controlled studies of the effect of buflomedil on intermittent claudication. ( Mac Hannaford, JC; Walker, GA, 1995)
" Buflomedil, a vasoactive substance with hemorheological properties, has been widely used in the treatment of intermittent claudication."9.09Clinical and hemorheological effects of buflomedil in diabetic subjects with intermittent claudication. ( Diamantopoulos, EJ; Grigoriadou, M; Ifanti, G; Raptis, SA, 2001)
"To evaluate the available evidence on the efficacy of buflomedil for intermittent claudication."8.81Buflomedil for intermittent claudication. ( Bogaert, MG; De Backer, TL; Vander Stichele, RH, 2001)
" This issue of bias in benefit-risk assessment of older products is illustrated here with an example: buflomedil in intermittent claudication."7.75Bias in benefit-risk appraisal in older products: the case of buflomedil for intermittent claudication. ( De Backer, TL; Van Bortel, LM; Vander Stichele, RH, 2009)
"Pentoxifylline was significantly more effective (P < 0."6.67Comparative evaluation of pentoxifylline, buflomedil, and nifedipine in the treatment of intermittent claudication of the lower limbs. ( Calleja, F; Casares, J; Chacón-Quevedo, A; Concha, M; Eguaras, MG; Garcia, MA; Muñoz, I; Roman, M, 1994)
"Buflomedil is a vasoactive agent widely used in the treatment of peripheral arterial disease."6.66[Comparison of the effectiveness of intra-arterial and intravenous administration of buflomedil in patients with intermittent claudication]. ( Diehm, C; Eckstein, M; Hübsch-Müller, C, 1989)
"Buflomedil is a vasoactive agent used to treat peripheral vascular disease."6.49Buflomedil for intermittent claudication. ( de Backer, TL; Vander Stichele, R, 2013)
"Buflomedil is a vasoactive agent used to treat peripheral vascular disease."6.44Buflomedil for intermittent claudication. ( Bogaert, M; de Backer, TL; Vander Stichele, R, 2007)
"Buflomedil is a vasoactive agent used to treat peripheral vascular disease."6.44Buflomedil for intermittent claudication. ( Bogaert, M; de Backer, TL; Vander Stichele, R, 2008)
" According to our results, buflomedil is more effective and safe than naftidrofuryl in the treatment of patients with intermittent claudication."5.26Comparison of safety and efficacy of buflomedil and naftidrofuryl in the treatment of intermittent claudication. ( Cerdeyra, C; Lucas, MA; Parano, JR; Rosas, G; Villa, JJ, 1981)
" We performed an international, multicenter, randomized, double-blind, placebo-controlled trial to investigate whether long-term administration of oral buflomedil could reduce the rate of cardiovascular events in patients with intermittent claudication."5.13Oral buflomedil in the prevention of cardiovascular events in patients with peripheral arterial obstructive disease: a randomized, placebo-controlled, 4-year study. ( Becker, F; Leizorovicz, A, 2008)
" The study, controlled, single blinded, enrolled 123 patients with intermittent claudication that were randomised in two groups; the first group received a treatment with PGE-1 while the second one received a pentoxifylline-buflomedil association by venous infusion."5.12The effects of prostaglandin E-1 in patients with intermittent claudication. ( Coppola, G; Milio, G; Novo, S, 2006)
" Buflomedil, a vasoactive substance with hemorheological properties, has been widely used in the treatment of intermittent claudication."5.09Clinical and hemorheological effects of buflomedil in diabetic subjects with intermittent claudication. ( Diamantopoulos, EJ; Grigoriadou, M; Ifanti, G; Raptis, SA, 2001)
" This issue of bias in benefit-risk assessment of older products is illustrated here with an example: buflomedil in intermittent claudication."3.75Bias in benefit-risk appraisal in older products: the case of buflomedil for intermittent claudication. ( De Backer, TL; Van Bortel, LM; Vander Stichele, RH, 2009)
"Food and Drug Administration for the treatment of intermittent claudication, several supplements and investigational agents have been evaluated."2.45Pharmacologic therapy for intermittent claudication. ( Dobesh, PP; Persson, EL; Stacy, ZA, 2009)
"Treatment with buflomedil for 3 months led to a significant improvement in signs and symptoms in all four clinical stages."1.27[Epidemiologic study of peripheral obstructive arteriopathies: clinical effects of treatment with buflomedil chlorhydrate (Loftyl). Processing of data furnished by a polycenter study]. ( , 1985)
" According to our results, buflomedil is more effective and safe than naftidrofuryl in the treatment of patients with intermittent claudication."1.26Comparison of safety and efficacy of buflomedil and naftidrofuryl in the treatment of intermittent claudication. ( Cerdeyra, C; Lucas, MA; Parano, JR; Rosas, G; Villa, JJ, 1981)

Research

Studies (38)

TimeframeStudies, this research(%)All Research%
pre-199013 (34.21)18.7374
1990's10 (26.32)18.2507
2000's13 (34.21)29.6817
2010's2 (5.26)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
de Backer, TL7
Vander Stichele, R3
Vander Stichele, RH4
Van Bortel, LM2
Dobesh, PP1
Stacy, ZA1
Persson, EL1
Tryniszewski, W1
Nowak, D1
Brocki, M1
Maziarz, Z1
Rysz, J1
Landi, A1
Neri, C1
Barbareschi, M1
Turrina, S1
De Leo, D1
Milio, G1
Coppola, G1
Novo, S1
Bogaert, M2
Leizorovicz, A1
Becker, F1
Conte, MS1
Trübestein, G2
Balzer, K2
Bisler, H2
Klüken, N2
Muller-Wiefel, H2
Unkel, B2
Mahfoud, Y2
Ziegler, W2
Marshall, M1
Forconi, S1
Pieragalli, D1
Acciavatti, A1
Del Bigo, C1
Galigani, C1
Ralli, L1
Guerrini, M1
Di Perri, T1
Dubourg, A1
Scamuffa, RF1
Rosas, G1
Cerdeyra, C1
Lucas, MA1
Parano, JR1
Villa, JJ1
Sunder-Plassmann, L1
Chacón-Quevedo, A1
Eguaras, MG1
Calleja, F1
Garcia, MA1
Roman, M1
Casares, J1
Muñoz, I1
Concha, M1
Walker, GA1
Mac Hannaford, JC1
Van den Brande, P1
Maurel, A1
Riambau, V1
Piñol, C1
Pérez Encinas, M1
Fernández, MA1
Martín, ML1
Calvo, MV1
Gómez-Alonso, A1
Dominguez-Gil, A1
Lozano, F1
Warie, HH1
Bogaert, MG2
Diamantopoulos, EJ1
Grigoriadou, M1
Ifanti, G1
Raptis, SA1
Weiss, T1
Fujita, Y1
Kreimeier, U1
Messmer, K1
Diehm, C2
Ehrly, AM1
Saeger-Lorenz, K1
Andreozzi, GM1
Lepore, R1
Scheffler, A1
Rieger, H1
Eckstein, M1
Hübsch-Müller, C1
Visconti, W1
Grillo, N1
Fonseca, V1
Mikhailidis, DP1
Barradas, MA1
Jeremy, JY1
Gracey, L1
Dandona, P1
Heidrich, H1
Dorigo, B1
Raspanti, D1
Trapani, M1
Albanese, B1
Cameli, AM1
Digiesi, V1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Prospective, Open, Non-randomized Phase I/II Study of Therapeutic Angiogenesis in Diabetic Patients With Critic Ischemia of Lower Limbs While Administering Positive CD133 Mobilized With G-CSF[NCT00765050]Phase 1/Phase 213 participants (Actual)Interventional2009-01-31Terminated
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

10 reviews available for buflomedil and Intermittent Claudication

ArticleYear
Buflomedil for intermittent claudication.
    The Cochrane database of systematic reviews, 2013, Mar-28, Issue:3

    Topics: Administration, Oral; Double-Blind Method; Humans; Intermittent Claudication; Publication Bias; Pyrr

2013
Pharmacologic therapy for intermittent claudication.
    Pharmacotherapy, 2009, Volume: 29, Issue:5

    Topics: Cilostazol; Clinical Trials as Topic; Dietary Supplements; Drugs, Investigational; Exercise Therapy;

2009
[Secondary prevention and conservative therapy of obliterative arteriosclerosis].
    Orvosi hetilap, 2004, May-16, Volume: 145, Issue:20

    Topics: Arteriosclerosis Obliterans; Cilostazol; Clinical Trials as Topic; Epoprostenol; Exercise; Hematolog

2004
Buflomedil for intermittent claudication.
    The Cochrane database of systematic reviews, 2007, Oct-17, Issue:4

    Topics: Administration, Oral; Double-Blind Method; Humans; Intermittent Claudication; Publication Bias; Pyrr

2007
Buflomedil for intermittent claudication.
    The Cochrane database of systematic reviews, 2008, Jan-23, Issue:1

    Topics: Administration, Oral; Double-Blind Method; Humans; Intermittent Claudication; Publication Bias; Pyrr

2008
An experimental overview of a new vasoactive drug: buflomedil HCl.
    Angiology, 1981, Volume: 32, Issue:10

    Topics: Animals; Cerebrovascular Disorders; Chronic Disease; Coronary Disease; Dogs; Hemodynamics; Humans; I

1981
A meta-analysis of randomized, double-blind, placebo-controlled studies of the effect of buflomedil on intermittent claudication.
    Fundamental & clinical pharmacology, 1995, Volume: 9, Issue:4

    Topics: Double-Blind Method; Exercise Test; Female; Humans; Intermittent Claudication; Male; Multicenter Stu

1995
[Intermittent claudication: review of a disease of growing prevalence. II. Treatment].
    Medicina clinica, 1998, Feb-21, Volume: 110, Issue:6

    Topics: Adrenergic alpha-Antagonists; Algorithms; Blood Vessel Prosthesis Implantation; Clinical Trials as T

1998
Oral vasoactive medication in intermittent claudication: utile or futile?
    European journal of clinical pharmacology, 2000, Volume: 56, Issue:3

    Topics: Administration, Oral; Humans; Intermittent Claudication; Nafronyl; Pentoxifylline; Pyrrolidines; Ran

2000
Buflomedil for intermittent claudication.
    The Cochrane database of systematic reviews, 2001, Issue:1

    Topics: Administration, Oral; Double-Blind Method; Humans; Intermittent Claudication; Publication Bias; Pyrr

2001

Trials

14 trials available for buflomedil and Intermittent Claudication

ArticleYear
Letter by De Backer et al regarding article, "Oral buflomedil in the prevention of cardiovascular events in patients with peripheral arterial obstructive disease: a randomized, placebo-controlled, 4-year study".
    Circulation, 2008, Sep-02, Volume: 118, Issue:10

    Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Disease Progr

2008
The effects of prostaglandin E-1 in patients with intermittent claudication.
    Cardiovascular & hematological disorders drug targets, 2006, Volume: 6, Issue:2

    Topics: Adult; Aged; Alprostadil; Drug Combinations; Exercise Test; Female; Humans; Infusions, Intravenous;

2006
Oral buflomedil in the prevention of cardiovascular events in patients with peripheral arterial obstructive disease: a randomized, placebo-controlled, 4-year study.
    Circulation, 2008, Feb-12, Volume: 117, Issue:6

    Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Disease Progr

2008
Buflomedil in arterial occlusive disease: results of a controlled multicenter study.
    Angiology, 1984, Volume: 35, Issue:8

    Topics: Aged; Arterial Occlusive Diseases; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Hu

1984
[Buflomedil in arterial occlusive disease. Results of a controlled study].
    Deutsche medizinische Wochenschrift (1946), 1982, Dec-24, Volume: 107, Issue:51-52

    Topics: Aged; Arterial Occlusive Diseases; Clinical Trials as Topic; Double-Blind Method; Female; Femoral Ar

1982
Comparative evaluation of pentoxifylline, buflomedil, and nifedipine in the treatment of intermittent claudication of the lower limbs.
    Angiology, 1994, Volume: 45, Issue:7

    Topics: Adult; Aged; Blood Pressure; Double-Blind Method; Exercise Test; Humans; Intermittent Claudication;

1994
A meta-analysis of randomized, double-blind, placebo-controlled studies of the effect of buflomedil on intermittent claudication.
    Fundamental & clinical pharmacology, 1995, Volume: 9, Issue:4

    Topics: Double-Blind Method; Exercise Test; Female; Humans; Intermittent Claudication; Male; Multicenter Stu

1995
A placebo-controlled study of the effects of intravenous Buflomedil on foot skin microcirculation in patients with severe intermittent claudication.
    Angiology, 1998, Volume: 49, Issue:2

    Topics: Aged; Aged, 80 and over; Arterial Occlusive Diseases; Chronic Disease; Dose-Response Relationship, D

1998
Clinical and hemorheological effects of buflomedil in diabetic subjects with intermittent claudication.
    International angiology : a journal of the International Union of Angiology, 2001, Volume: 20, Issue:4

    Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Erythrocyte Deformability; Female; Hemorheology; Hum

2001
[Action and tolerability of delayed-action buflomedil in obliterating arteriopathies of the lower limbs. A multicenter study].
    La Clinica terapeutica, 1990, Nov-30, Volume: 135, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arterial Occlusive Diseases; Delayed-Action Preparations

1990
[Acral skin circulation following intra-arterial infusion of vasodilating substances in patients with intermittent claudication].
    Medizinische Klinik (Munich, Germany : 1983), 1990, Jan-15, Volume: 85, Issue:1

    Topics: Aged; Alprostadil; Fluorescein Angiography; Foot; Humans; Intermittent Claudication; Male; Middle Ag

1990
[Comparison of the effectiveness of intra-arterial and intravenous administration of buflomedil in patients with intermittent claudication].
    VASA. Zeitschrift fur Gefasskrankheiten, 1989, Volume: 18, Issue:1

    Topics: Clinical Trials as Topic; Female; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Intermi

1989
Double-blind placebo-controlled trial of buflomedil in intermittent claudication.
    International journal of clinical pharmacology research, 1988, Volume: 8, Issue:5

    Topics: Aged; Blood Pressure; Double-Blind Method; Female; Humans; Intermittent Claudication; Male; Middle A

1988
[Vasoactive drugs in peripheral arterial perfusion disorders. Problems, principles and results of the determination of therapeutic efficacy].
    Deutsche medizinische Wochenschrift (1946), 1985, Aug-02, Volume: 110, Issue:31-32

    Topics: Arterial Occlusive Diseases; Cardiovascular Agents; Cinnarizine; Clinical Trials as Topic; Dihydroer

1985

Other Studies

15 other studies available for buflomedil and Intermittent Claudication

ArticleYear
Bias in benefit-risk appraisal in older products: the case of buflomedil for intermittent claudication.
    Drug safety, 2009, Volume: 32, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Databases, Factual; Drug-Related Side Effects and Adverse R

2009
Influence of pharmacological treatment on blood flow and muscle perfusion in patients with obliterative atheromatosis assessed with isotopic methods. A pilot study.
    Medical science monitor : international medical journal of experimental and clinical research, 2010, Volume: 16, Issue:12

    Topics: Analysis of Variance; Arteriosclerosis Obliterans; Aspirin; Blood Flow Velocity; Exercise; Female; H

2010
Suicide by buflomedil HCl: a case report.
    Journal of clinical forensic medicine, 2004, Volume: 11, Issue:1

    Topics: Drug Overdose; Gas Chromatography-Mass Spectrometry; Humans; Intermittent Claudication; Male; Middle

2004
Buflomedil in peripheral arterial disease: trials and tribulations.
    Circulation, 2008, Feb-12, Volume: 117, Issue:6

    Topics: Adrenergic alpha-Antagonists; Cardiovascular Diseases; Disease Progression; Humans; Intermittent Cla

2008
[Arterio-vascular diseases. New trends in diagnosis and therapy].
    MMW, Munchener medizinische Wochenschrift, 1983, May-13, Volume: 125, Issue:19

    Topics: Arterial Occlusive Diseases; Humans; Intermittent Claudication; Pyrrolidines; Vasodilator Agents

1983
Positive effect of oral buflomedil on exercise-induced haemorheological damage and on claudication distance in peripheral obliterative arterial disease patients.
    The Journal of international medical research, 1984, Volume: 12, Issue:3

    Topics: Administration, Oral; Arterial Occlusive Diseases; Blood Viscosity; Female; Humans; Hydrogen-Ion Con

1984
Comparison of safety and efficacy of buflomedil and naftidrofuryl in the treatment of intermittent claudication.
    Angiology, 1981, Volume: 32, Issue:5

    Topics: Butyrophenones; Double-Blind Method; Evaluation Studies as Topic; Furans; Humans; Intermittent Claud

1981
[Improved microcirculation and collateral circulation in arterial occlusive diseases of the lower extremity].
    Fortschritte der Medizin, 1981, Nov-19, Volume: 99, Issue:43

    Topics: Animals; Arterial Occlusive Diseases; Collateral Circulation; Dogs; Hemodilution; Hindlimb; Intermit

1981
Multicriteria decision analysis for determining drug therapy for intermittent claudication.
    Methods and findings in experimental and clinical pharmacology, 1998, Volume: 20, Issue:5

    Topics: Decision Support Techniques; Humans; Intermittent Claudication; Nafronyl; Pentoxifylline; Probabilit

1998
Effect of intensive walking exercise on skeletal muscle blood flow in intermittent claudication.
    Angiology, 1992, Volume: 43, Issue:1

    Topics: Administration, Oral; Animals; Combined Modality Therapy; Dogs; Drug Evaluation, Preclinical; Exerci

1992
[Possibilities and limits of physical training therapy of intermittent claudication patients with simultaneous drug therapy].
    VASA. Supplementum, 1991, Volume: 32

    Topics: Alprostadil; Combined Modality Therapy; Exercise; Follow-Up Studies; Humans; Intermittent Claudicati

1991
Exercise-induced variations in muscle tissue oxygen pressure in claudicants: effects of buflomedil.
    Blood vessels, 1991, Volume: 28 Suppl 1

    Topics: Adult; Aged; Exercise; Humans; Intermittent Claudication; Middle Aged; Muscles; Oxygen Consumption;

1991
[Buflomedil in the treatment of chronic peripheral arterial diseases. Case contribution].
    Minerva medica, 1985, May-12, Volume: 76, Issue:19-20

    Topics: Aged; Arterial Occlusive Diseases; Drug Tolerance; Female; Humans; Intermittent Claudication; Male;

1985
[Flowmetric, thermometric and rheologic studies in obliterating arterial diseases of the lower extremities treated with buflomedil].
    Minerva medica, 1985, Feb-25, Volume: 76, Issue:7

    Topics: Aged; Arterial Occlusive Diseases; Blood Flow Velocity; Blood Viscosity; Drug Administration Schedul

1985
[Epidemiologic study of peripheral obstructive arteriopathies: clinical effects of treatment with buflomedil chlorhydrate (Loftyl). Processing of data furnished by a polycenter study].
    Minerva medica, 1985, Oct-13, Volume: 76, Issue:39

    Topics: Administration, Oral; Age Factors; Aged; Arterial Occlusive Diseases; Female; Humans; Infusions, Par

1985